Minimally invasive endoscopic treatment of gastric leiomyosarcoma: A rare case report and review of literature

Gastrointestinal leiomyosarcoma remains relatively rare,accounting for only 1% of gastric tumors,since the use of c-kit staining was first described in 1998 to differentiate gastrointestinal stromal tumors.In this case report,we described the clinical manifestations,endoscopic features, and pathological immunohistochemical features of the gastric leiomyosarcoma.We found that endoscopic ultrasonography has great value in the diagnosis of gastric leiomyosarcoma,and that minimally invasive endoscopic treatment is safe and effective.Particularly,this case highlights that the early-stage lesions can be treated with minimally invasive endoscopic treatment with good tolerance and satisfactory clinical results.Endoscopic submucosal dissection is thus effective for treating gastric leiomyosarcoma,with promising prospects for clinical application.

Long lasting response of trabectedin in patient with gastric leiomyosarcoma with liver metastasis: an update to previous report

Leiomyosarcoma of the stomach is an extremely rare malignancy for which treatment in advanced disease is hardly reported. Here, we report a case of a 48-year-old man with metastatic gastric Leiomyosarcoma who had previously received a combination of gemcitabine and docetaxel followed by pazopanib after detection of metastasis. The patient was started on trabectedin as per protocol and had disease control continuing for 17 cycles of trabectedin. His quality of life and absence of significant toxicities highlight the noncumulative nature of trabectedin and potential benefit in responding cases.